Literature DB >> 1699401

Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer. A Southwest Oncology Group study.

D D Von Hoff1, S Green, E A Surwit, E V Hannigan, D S Alberts.   

Abstract

Twenty evaluable patients with advanced cervical cancer refractory to one prior chemotherapy regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicities were anemia and leukopenia. Based on this study, fludarabine phosphate does not appear to be an active agent for patients with chemotherapy refractory cervical cancer.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1699401     DOI： 10.1097/00000421-199010000-00014

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN： 0277-3732            Impact factor:   2.339


  6 in total

1.  A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.

Authors:  Sanja Stevanović; Sarah R Helman; John R Wunderlich; Michelle M Langhan; Stacey L Doran; Mei Li M Kwong; Robert P T Somerville; Christopher A Klebanoff; Udai S Kammula; Richard M Sherry; James C Yang; Steven A Rosenberg; Christian S Hinrichs
Journal:  Clin Cancer Res       Date:  2018-12-05       Impact factor: 12.531

2.  Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.

Authors:  Sanja Stevanović; Lindsey M Draper; Michelle M Langhan; Tracy E Campbell; Mei Li Kwong; John R Wunderlich; Mark E Dudley; James C Yang; Richard M Sherry; Udai S Kammula; Nicholas P Restifo; Steven A Rosenberg; Christian S Hinrichs
Journal:  J Clin Oncol       Date:  2015-03-30       Impact factor: 44.544

Review 3.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

4.  Ocular toxicity of fludarabine: a purine analog.

Authors:  Xiaoyan Ding; Alexandra A Herzlich; Rachel Bishop; Jingsheng Tuo; Chi-Chao Chan
Journal:  Expert Rev Ophthalmol       Date:  2008-02

Review 5.  Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.

Authors:  G Rodriguez
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

6.  Combined Effects of Fludarabine and Interferon Alpha on Autophagy Regulation Define the Phase of Cell Survival and Promotes Responses in LLC-MK2 and K562 Cells.

Authors:  Pathompong Bowornruangrit; Supeecha Kumkate; Wipawan Sirigulpanit; Vijittra Leardkamolkarn
Journal:  Med Sci (Basel)       Date:  2022-03-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.